Novartis drug approved by EU
Article Abstract:
Swiss pharmaceutical firm Novartis AG received approval by the European Union to market a generic version of epoetin alfa, an anti-anemia drug, in Europe. The non-generic version, Eprex, is marketed in Europe by Johnson and Johnson.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Novartis has potential blockbuster as FDA backs blood-pressure drug
Article Abstract:
The U.S. Food and Drug Administration has approved Swiss pharmaceutical company Novartis AG's blood pressure drug, Tekturna. This approval could result in billions of dollars of sales for Novartis.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Novartis comes to rescue of neurotic dogs. U.S. approves Glaxo treatment for depression. AstraZeneca's Crestor should get U.S. approval
- Abstracts: Novartis offers to buy rest of Chiron. Novartis agrees to acquire the rest of Chiron for $5.1 billion. Biotech industry heads toward IPO boomlet
- Abstracts: North Korea's block on food aid reflects regime push for control
- Abstracts: IT job growth is seen slowing for rest of year. As U.S. trade deficit narrows, prospects brighten for economy
- Abstracts: Belgacom unit in France to cut phone rates. Tailoring ads to email users, Google has some poor fits. Sony's new videogame camera posts strong sales in Europe